knowledge -WSS

knowledge

author：focus 2025-09-27 22:48:28 - browse：92

Gilead office remdesivir — Yichuan Cao/Sipa USA

Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.

The deal values CymaBay at $32.50 per share, 27% higher than the stock’s close last Friday. That’s a relatively small takeout premium, but CymaBay shares have doubled in value since last fall on growing investor confidence in the company’s lead drug and speculation that the company could be acquired.

CymaBay’s drug, called seladelpar, is being developed for the treatment of primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women that causes decreased liver function, and debilitating itching and fatigue. Progression of PBC to more advanced stages increases the risk of liver-related death.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Heart disease and mental health: A look at cardiac psychology

WSS

Medicare to cover more brain scans for Alzheimer’s patients

New England Journal of Medicine addresses racist history, slavery

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

As digital health tech proliferates, a new institute aims to cut through hype

As digital health tech proliferates, a new institute aims to cut through hype

New menopause drug shows promise in relief for hot flashes

focus

knowledge

entertainment

Trump demands the U.S. pay no more for drugs than other countries … again

Fauci’s Covid grilling leads GOP to weigh foreign research rules

Novavax promises a turnaround & Lilly roils the obesity market

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

As demand for Covid shots wanes, Moderna seeks its next success

HHS names first

At least 13 dead in Texas as scorching temps continue

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

After affirmative action ruling, medical educators look to 'holistic review'

Custom gene therapy hints at new path for rare disease treatments

Wikipedia

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

Sanofi seeks simpler, safer CRISPR sickle cell cure

Fauci’s Covid grilling leads GOP to weigh foreign research rules

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

leisure time

hotspot

focus

knowledge